



wherein Ab is an antibody or antigen binding fragment thereof, and y is an integer from 1 to 4.

**12-14.** (canceled)

**15.** The conjugate of claim **11**, wherein the compound is attached to cysteines at positions 152 and 375 of the antibody heavy chain (all positions by EU numbering).

**16.** The conjugate of claim **11**, wherein y is about 3 to 4.

**17.** The conjugate of claim **11**, wherein the conjugate has a hydrophobicity index of 0.8 or greater, as determined by hydrophobic interaction chromatography.

**18.** A pharmaceutical composition comprising one or more conjugates of claim **1** and a pharmaceutically acceptable carrier.

**19.** A pharmaceutical composition comprising one or more conjugates of claim **11** and a pharmaceutically acceptable carrier.

**20.** A method of treating a cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the conjugate of claim **1**.

**21.** (canceled)

**22.** The method of claim **20**, wherein the cancer is selected from gastric cancer, esophageal cancer, gastroesophageal junction adenocarcinoma, colon cancer, rectal cancer, breast cancer, ovarian cancer, cervical cancer, uterine cancer, endometrial cancer, bladder cancer, urinary tract cancer, pancreatic cancer, lung cancer, prostate cancer, osteosarcoma, neuroblastoma, glioblastoma, and head and neck cancer.

**23.** The method of claim **20**, wherein the conjugate is administered to the subject intravenously, intratumorally, or subcutaneously.

**24.** The method of claim **20**, wherein the conjugate is administered at a dose of about 0.01-20 mg per kg of body weight.

**25.** The method of claim **20** further comprising administering a second agent to the subject.

**26-33.** (canceled)

\* \* \* \* \*